Revance Therapeutics SG&A Expense (Quarterly) Analysis

Revance Therapeutics Inc (RVNC)

2.65 -0.22 (-7.67%) USD | NASDAQ | Jun 21, 16:00

2.66 +0.01 (+0.38%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2012. Upgrade now.

Date	Value
March 31, 2024	68.91M
December 31, 2023	84.30M
September 30, 2023	67.73M
June 30, 2023	76.34M
March 31, 2023	61.92M
December 31, 2022	64.19M
September 30, 2022	64.74M
June 30, 2022	46.83M
March 31, 2022	43.94M
December 31, 2021	49.30M
September 30, 2021	51.77M
June 30, 2021	49.68M
March 31, 2021	48.07M
December 31, 2020	53.98M
September 30, 2020	47.51M
June 30, 2020	29.37M
March 31, 2020	20.98M
December 31, 2019	19.39M
September 30, 2019	16.50M
June 30, 2019	13.60M
March 31, 2019	12.91M
December 31, 2018	13.36M
September 30, 2018	14.16M

Date	Value
June 30, 2018	12.73M
March 31, 2018	13.62M
December 31, 2017	11.89M
September 30, 2017	9.148M
June 30, 2017	8.609M
March 31, 2017	7.754M
December 31, 2016	7.10M
September 30, 2016	7.502M
June 30, 2016	7.018M
March 31, 2016	7.455M
December 31, 2015	6.905M
September 30, 2015	5.827M
June 30, 2015	6.36M
March 31, 2015	5.996M
December 31, 2014	4.793M
September 30, 2014	5.30M
June 30, 2014	4.857M
March 31, 2014	4.093M
December 31, 2013	3.003M
September 30, 2013	2.142M
June 30, 2013	3.641M
March 31, 2013	2.225M
December 31, 2012	1.614M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

13.60M

Minimum

Jun 2019

84.30M

Maximum

Dec 2023

48.95M

Average

49.49M

Median

SG&A Expense (Quarterly) Benchmarks